Company

ArtiFex Medical GmbH, founded in 2020 in Vienna as a spin-off from University Hospital Basel, develops a vascular graft platform based on bacterial cellulose. Our approach combines a naturally biocompatible material with controlled, reproducible manufacturing to deliver reliable small-diameter grafts.

Investors
Our work is supported by funding from the FFG (Austrian Research Promotion Agency), by NLC Health Ventures, and by committed angel investors, enabling the scientific, technical and preclinical development of our vascular graft platform.

TEAM

Expertise Across Biology, Engineering and Clinical Translation

Erich Groesslinger CEO

Brings extensive med-tech leadership in therapy development, commercialization and organizational execution. He drives strategy, partnerships and the transition from technology to clinical and market adoption.

Bernhard Winkler Founder & CMO

Provides the clinical foundation of the project as a cardiac surgeon and inventor. He guides graft design, surgical usability and clinical validation to ensure strong relevance for CABG and dialysis applications.

Marie Ebeyer-Masotta R&D Manager

Leads scientific development with expertise in biomaterials, graft characterization and translational engineering. She ensures the technology meets preclinical, regulatory and manufacturability requirements.

Henk Westendorp NLC Health Ventures

Contributes venture-building experience across R&D, early commercialization and med-tech scale-up, enabling a clear pathway from innovation to a sustainable company.